MitoPRO X
6 wavelengths, touchscreen, app control. Medical-grade performance.
from $449.00
MitoADAPT 4.0
8 wavelengths, 11 modes, patent-pending TruDUAL™ chip technology.
from $549.00
MitoPRO+
4 wavelengths, exceptional power, unbeatable value.
from $369.00
Mito Red Original 2.0
660nm + 850nm. ETL certified. Great value starting point.
from $249.00
MitoAURA Complete System
MitoAURA 3-Step System is the first skincare protocol engineered to work with your red and near-infrared light therapy sessions, not just alongside them.
from $93.00
MitoAURA Serum
Light-responsive. Firms, brightens, and amplifies every session.
from $40.00
MitoGLOW Mask
FDA-cleared LED mask. 1,064 LEDs, 4 wavelengths, 5 modes.
from $499.00
MitoAURA™ Gentle Cleanser
Gently cleanses without stripping skin's natural moisture.
from $25.00
MitoAURA™ Prime Pre-LED Serum
Helps prepare and condition skin for red light therapy.
from $39.00
MitoAURA™ Seal Post LED Moisturizer
Helps lock in moisture and support long-lasting hydration.
from $39.00
MitoPRO Mobile
5 wavelengths, pulse mode, UL-listed battery. Pro light anywhere.
from $349.00
MitoQUAD Belt
Hands-free wearable belt. UL medical grade, 4 wavelengths.
from $349.00
MitoPOD
Full-body pod. IEC 60601 certified, 6,960 LEDs total.
from $1,699.00
MitoBOOST
Intranasal device. Red, blue & NIR for sinus, immune & brain.
from $199.00
What is Red Light Therapy
The science behind PBM — how red and near-infrared light works at the cellular level.
The Mito Red Difference
Why our devices outperform — specs, certifications, and build quality explained.
In the Press
Media coverage, expert reviews, and editorial features.
FAQ
Common questions about devices, protocols, safety, and shipping.
Take the Quiz
Four quick questions to find the right panel for your goals.
Research & Evidence
Browse the clinical studies and data behind photobiomodulation therapy.
Community
Meet the Mito Red community — real people, real results.
Four quick questions. One recommendation.
By treatment area
Formulated to work with light — not just alongside it. Young Goose collab. EWG Green. Made in USA.
BEST VALUE
COMING SOON
STEP 1
STEP 2
STEP 3
About the research on this page. The studies cited here investigate photobiomodulation (PBM) as a therapeutic modality and the specific wavelengths used in PBM research — not Mito Red Light devices. The wavelengths in our panels were chosen because the peer-reviewed PBM literature supports them. Evidence levels and study counts reflect the broader research base, not studies of our products. See the full methodology note at the bottom of this page.
Brain research on light therapy is promising in some areas and null in others. A 2026 meta-analysis found a moderate reduction in depressive symptoms, with larger effects from whole-body than transcranial light and from longer treatment (Seok 2026). A 2025 meta-analysis of randomized trials found improvements in global cognition, working memory and executive function in people with cognitive impairment, and partial gains in healthy people (Zhu 2025). Five trials (240 participants) showed better sleep quality scores than sham, though the estimate was imprecise (Vital de Azevedo 2026). For Bell's palsy, 12 studies (597 patients) found better facial function with laser therapy (Lin 2024).
Two larger questions have null answers so far. A 2025 Cochrane review found little to no difference in function or survival with transcranial laser after acute ischemic stroke (He 2025). A 2026 meta-analysis of Parkinson's disease found light therapy safe but without clinically meaningful motor benefits (Mariano 2026).
Based on 1203 indexed studies in this category, 365 of them in people. These studies test photobiomodulation in general, not Mito Red Light devices.
Number of studies in our database for each condition. Direction and certainty are shown only where a meta-analysis or systematic review reports them; otherwise the row says "not graded".
| Condition | Human randomized trials | All human studies | Direction of results | Certainty |
|---|---|---|---|---|
| Tinnitus | 22 | 31 | Not graded | Not graded |
| Diabetic neuropathy | 20 | 28 | Not graded | Not graded |
| Alzheimer's Disease | 16 | 24 | Not graded | Not graded |
| CNS: Bell's palsy | 10 | 23 | Better facial function and symmetry Lin 2024 (PMID 39546047) |
Not graded by authors |
| Cognitive performance | 17 | 20 | Improved cognition, mainly in cognitive impairment Zhu 2025 (PMID 40394373) |
Not graded; high heterogeneity |
| Depression | 13 | 19 | Moderate reduction in depressive symptoms Seok 2026 (PMID 41101469) |
Not graded; heterogeneous protocols |
| Brain injury | 2 | 16 | Not graded | Not graded |
| EEG | 14 | 15 | Not graded | Not graded |
| Stroke (clinical) | 10 | 15 | Little to no difference after acute ischemic stroke He 2025 (PMID 40704566) |
Low to moderate (Cochrane) |
| Parkinson's disease | 7 | 14 | No clinically meaningful motor benefit Mariano 2026 (PMID 42793350) |
Not graded; small trials |
| Sleep quality | 10 | 13 | Not graded | Not graded |
| Brain | 4 | 12 | Not graded | Not graded |
| Cognitive impairment | 5 | 9 | Not graded | Not graded |
| Functional connectivity | 6 | 8 | Not graded | Not graded |
| Spinal cord | 4 | 7 | Not graded | Not graded |
The strongest human evidence: systematic reviews and meta-analyses first, then the newest randomized trials. Each card comes straight from our study database and links to the paper.
Seok et al., J Affect Disord, 2026. PMID 41101469
Zhu et al., Lasers Med Sci, 2025. PMID 40394373
de Azevedo et al., Lasers Med Sci, 2026. PMID 42322437
Mariano et al., Brain Sci, 2026. PMID 42793350
He et al., Cochrane Database Syst Rev, 2025. PMID 40704566
Lin et al., Lasers Med Sci, 2024. PMID 39546047
Not every trial is positive. "No effect" means the main outcome did not differ from sham or control. "Mixed" means some outcomes improved but the outcome named here did not differ.
| Year | Study | Design | Result | Outcome with no difference |
|---|---|---|---|---|
| 2026 | The Effect of Transcranial Near-infrared Laser Therapy on Chronic Ischemic Stroke Patients: A Randomized, Single-blind, Sham-controlled Trial | RCT, n = 40 | No effect | Stroke recovery versus sham, added to rehabilitation |
| 2025 | Effectiveness of Photobiomodulation to Treat Motor and Non-Motor Symptoms of Parkinson's Disease: A Randomised Clinical Trial with Extended Treatment | RCT | No effect | Timed up-and-go (primary) versus sham in Parkinson's disease |
| 2026 | Dose dependent effects of transcranial photobiomodulation on blood-oxygenation-level-dependent power in major depressive disorder | RCT, n = 31 | Mixed | Depression severity after single sessions (brain blood-flow signal changed) |
The 25 most recent human studies in our database for this category.
Wavelengths reported in our database for the 217 human randomized trials in this category (78 wavelength entries; many database records lack a wavelength, and some trials report more than one). This describes the research; it is not a dosing recommendation.
| Wavelength band | Times used in trials |
|---|---|
| Near-infrared (800-899 nm) | 34 |
| Red (600-699 nm) | 23 |
| Near-infrared (900-1200 nm) | 13 |
| Blue/green (400-599 nm) | 5 |
| Deep red/near-infrared (700-799 nm) | 3 |
Most common wavelengths: 1060-1069 nm, 800-809 nm, 630-639 nm, 810-819 nm, 850-859 nm.
A 2026 meta-analysis found a moderate reduction in depressive symptoms (Hedges' g -0.47), with larger effects from whole-body light and longer treatment (Seok 2026).
A 2025 meta-analysis of randomized trials found improvements in global cognition, working memory and executive function in people with cognitive impairment, but advised caution because of heterogeneity (Zhu 2025).
Five randomized trials showed better sleep quality scores than sham, but the estimate is imprecise and the evidence is limited (Vital de Azevedo 2026).
Not so far. A Cochrane review found little to no benefit after acute ischemic stroke (He 2025), and a 2026 meta-analysis found no clinically meaningful motor benefit in Parkinson's disease (Mariano 2026).
All 1203 studies in this category from our study database, built on the PBM Research Database by Vladimir Heiskanen.
Search every study across all categories: Open the Full Evidence Explorer →
The published research indexed and referenced on this page studies photobiomodulation (PBM) as a therapeutic modality and the specific wavelengths used in those studies — not Mito Red Light devices specifically. The wavelengths used across our panels were chosen because the peer-reviewed PBM literature supports them: this is where published evidence is deepest, where dosing parameters have been characterized in human studies, and where clinical guidelines (such as WALT for inflammation and pain) exist. Mito Red Light has not funded or conducted registered clinical trials on our specific devices, and the study counts referenced here reflect the broader PBM research base — not studies of our products.
Where review authors graded certainty (for example with GRADE), we report their grade; other ratings are Mito’s summary. Study counts reflect peer-reviewed photobiomodulation research drawn from major scientific literature databases, peer-reviewed journals, and other published research repositories. PBM response varies meaningfully by person, tissue, condition, dose, wavelength, and session timing; outcomes reported in the published literature may not be replicable for every user. Mito Red Light devices are not intended to diagnose, treat, cure, or prevent any disease. If you have a medical condition or are under a physician’s care, please consult your healthcare provider before beginning any photobiomodulation regimen.
